[Anti-arrhythmic effectiveness of allapinin in ventricular arrhythmia in patients with circulatory failure]

Antiarrhythmic efficacy of allapinin was assessed in 15 patients with heart failure combined with ventricular arrhythmias (48 h ECG monitoring). The drug was administered against a background of maintenance therapy with digoxin at a daily dose of 75 mg (digoxin concentration in blood plasma was 1.51 +/- 0.12 ng/ml). The drug was shown to possess marked antiarrhythmic activity causing a decrease of the total number of ventricular extra systoles by an average of 72.3%, group ventricular extrasystoles--by 84.5%. The drug can be recommended in combination with cardiac glycosides to patients with severe heart failure combined with ventricular arrhythmias.